Nurix Therapeutics(US:NRIX) Benzinga·2025-10-10 12:02Summary of Key Points Core Viewpoint - U.S. stock futures showed slight gains, while several companies reported disappointing financial results leading to significant pre-market trading declines in their shares [1][4]. Company-Specific Summaries - Nurix Therapeutics Inc (NASDAQ:NRIX): - Reported a quarterly loss of $1.03 per share, worse than the expected loss of $0.88 per share - Sales were $7.894 million, missing expectations of $16.736 million - Shares fell 5.8% to $10.24 in pre-market trading [1][2]. - Venture Global, Inc. (NYSE:VG): - Shares dipped 18.4% to $10.27 following a resolution related to an arbitration proceeding concerning the Calcasieu Pass facility [4]. - Orthopediatrics Corp (NASDAQ:KIDS): - Shares fell 15% to $15.25 after the company cut its FY25 revenue guidance [4]. - Inventiva S.A. (NYSE:IVA): - Shares declined 13.6% to $4.78 in pre-market trading [4]. - USANA Health Sciences Inc (NYSE:USNA): - Shares declined 13% to $22.83 after reporting preliminary results for the third quarter, with an adjusted loss of $0.15 per share and sales of $214 million [4]. - Nanobiotix S.A. (NASDAQ:NBTX): - Shares declined 8.1% to $27.48 after a previous gain of 10% [4]. - Diginex Limited (NASDAQ:DGNX): - Shares fell 7.6% to $29.00 in pre-market trading [4]. - Levi Strauss & Co (NYSE:LEVI): - Reported quarterly earnings of $0.34 per share, beating the analyst consensus estimate of $0.31 per share - Quarterly sales were $1.543 billion, exceeding the analyst consensus estimate of $1.501 billion - Shares tumbled 7.1% to $22.81 in pre-market trading [4].